百濟神州(06160.HK):根據股份計劃發行新股份
格隆匯5月14日丨百濟神州(06160.HK)發佈公吿,2018年12月7日,公司股東批准第二份經修訂及重列2016期權及激勵計劃(經修訂,“2016年計劃”)。於2020年、2022年及2024年,公司股東已批准多份2016年計劃修訂,以增加2016年計劃項下供發行的授權股份數目,持續提供激勵機會。公司謹此宣佈,與存續註冊相關,於2025年5月13日(美國時間),公司同意應向BGNC2(公司的一間全資附屬公司)配發及發行1.33億股新股份,該等股份乃為承授人的利益所持有,以滿足公司根據2016年計劃及依據公司股東按照香港上市規則第17章批准的屆時可用的計劃授權限額向承授人授予的尚未行使或歸屬的股權獎勵。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.